Dr. Baca is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Boston, MA 02115Phone+1 617-732-5500Fax+1 617-632-2165
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2017 - 2021
- Brigham and Women's HospitalResidency, Internal Medicine, 2015 - 2018
- Harvard Medical SchoolClass of 2014
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- MA State Medical License 2015 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis.Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Arifa Bibi, Muhammad Ali Khan, Manal Imran
European Urology. 2025-01-22 - Structurally-oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes.Justin Hwang, Pornlada Likasitwatanakul, Sachin Kumar Deshmukh, Sharon Wu, Jason J Kwon
Clinical Cancer Research. 2025-01-02 - 3 citationsFirst-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study.Talal El Zarif, Karl Semaan, Wanling Xie, Marc Eid, Martin Zarba
European Urology. 2024-12-01
Press Mentions
- Precede Biosciences Unveils Groundbreaking Clinical Data for Its Pioneering Liquid Biopsy Platform at ESMO 2023 and Simultaneously Publishes in Nature MedicineOctober 22nd, 2023
- Lung, Kidney, and Neuroendocrine Tumor Cancer Studies Led by Dana-Farber Presented at ESMO Congress 2023October 26th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: